Screener
Viridian Therapeutics, Inc. VRDN Stock-Based Comp
Stock-Based Comp at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:31 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001590750-26-000018
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(232,020) | $(187,647) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Share-based compensation expense | 30,374 | 21,064 |
| Non-cash interest expense | 4,882 | 206 |
| Depreciation and amortization | 238 | 230 |
| Accretion and amortization of available-for-sale securities | (3,308) | (3,872) |
| Non-cash lease expense | (28) | (17) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Viridian Therapeutics, Inc.'s stock-based comp?
- Viridian Therapeutics, Inc. (VRDN) reported stock-based comp of $16.98M in Q2 2026.
- How has Viridian Therapeutics, Inc.'s stock-based comp changed year-over-year?
- Viridian Therapeutics, Inc.'s stock-based comp increased by 56.6% year-over-year, from $10.84M to $16.98M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Viridian Therapeutics, Inc.'s stock-based comp has grown at a 32.3% compound annual growth rate (CAGR), from $14.47M to $44.3M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Viridian Therapeutics, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude